Gene therapy for cerebral vascular disease: update 2003.
Gene therapy is a promising strategy for cerebrovascular diseases. Several genes that encode vasoactive products have been transferred via cerebrospinal fluid for the prevention of vasospasm after subarachnoid hemorrhage. Transfer of neuroprotective genes, including targeting of proinflammatory mediators, is a current strategy of gene therapy for ischemic stroke. Stimulation of growth of collateral vessels, stabilization of atherosclerotic plaques, inhibition of thrombosis, and prevention of restenosis are important objectives of gene therapy for coronary and limb arteries, but application of these approaches to carotid and intracranial arteries has received little attention. Several fundamental advances, including development of safer vectors, are needed before gene therapy achieves an important role in the treatment of cerebrovascular disease and stroke.
Department of Cerebrovascular Disease and Clinical Research Institute, National Kyushu Medical Center, Fukuoka 810-8563, Japan.
Kazunori
K
Toyoda
Yi
Y
Chu
Donald D
DD
Heistad
D000818:Animals; D001161:Arteriosclerosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D001921:Brain / Q000098:blood supply; D002545:Brain Ischemia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D003097:Collateral Circulation; D015316:Genetic Therapy; D006801:Humans; D013345:Subarachnoid Hemorrhage / Q000150:complications; D020301:Vasospasm, Intracranial / Q000209:etiology / Q000503:physiopathology / Q000628:therapy